TLT — Theralase Technologies Income Statement
0.000.00%
Last trade - 00:00- CA$48.20m
- CA$48.40m
- CA$1.03m
Annual income statement for Theralase Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.929 | 0.781 | 1.14 | 1.07 | 1.03 |
| Cost of Revenue | |||||
| Gross Profit | 0.27 | 0.31 | 0.628 | 0.562 | 0.554 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.53 | 5.19 | 6.37 | 5.64 | 5.29 |
| Operating Profit | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Net Income Before Taxes | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Net Income After Taxes | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.027 | -0.022 | -0.025 | -0.021 | -0.018 |